Global Leading Market Research Publisher QYResearch announces the release of its latest report “GMP Grade Cytokines – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/4799306/gmp-grade-cytokines
To Biopharmaceutical Executives, Cell Therapy Manufacturers, and Advanced Therapy Investors:
If your organization develops or manufactures cell-based therapies (CAR-T, TCR-T, NK cells, stem cells), immunotherapies, or regenerative medicine products, you face a persistent challenge: sourcing cytokines that meet stringent regulatory requirements for identity, purity, potency, endotoxin levels, and sterility. Research-grade cytokines are unsuitable for clinical applications due to batch variability, potential contaminants (endotoxins, residual process impurities), and lack of documentation. The solution lies in GMP grade cytokines —highly purified cytokine proteins manufactured under Good Manufacturing Practice (GMP) guidelines to ensure safety, consistency, and quality for use in clinical applications, including cell therapy, immunotherapy, and regenerative medicine. According to QYResearch’s newly released market forecast, the global GMP grade cytokines market was valued at US$1,326 million in 2024 and is projected to reach US$3,257 million by 2031, growing at a compound annual growth rate (CAGR) of 12.6 percent during the 2025-2031 forecast period. This exceptional growth reflects the rapid expansion of cell-based therapies globally, the increasing demand for high-quality, GMP-compliant cytokines, and the essential role these proteins play in T-cell expansion, dendritic cell maturation, and stem cell differentiation.
1. Product Definition: Cytokines Manufactured Under Strict Regulatory Standards
GMP grade cytokines are highly purified cytokine proteins manufactured under Good Manufacturing Practice (GMP) guidelines to ensure safety, consistency, and quality for use in clinical applications, including cell therapy, immunotherapy, and regenerative medicine. Cytokines—such as interleukins (IL), interferons (IFN), tumor necrosis factors (TNF), and growth factors (EGF, FGF, VEGF)—play critical roles in regulating immune responses and cell signaling. When produced to GMP standards, these cytokines meet strict regulatory requirements concerning identity, purity, potency, endotoxin levels, and sterility, making them suitable for direct use in human therapeutic products or clinical trials.
The production of GMP grade cytokines involves controlled manufacturing environments (cleanrooms, typically ISO 7 or ISO 8), validated processes (consistent production methods that ensure batch-to-batch reproducibility), rigorous quality control testing (identity verification by mass spectrometry or ELISA; purity by SDS-PAGE or HPLC; potency by bioassay; endotoxin levels by LAL test; sterility by compendial methods; and mycoplasma, virus, and adventitious agent testing), and comprehensive documentation (certificate of analysis, manufacturing batch records, stability data, regulatory support files). These standards help prevent contamination, batch variability, or other risks that could compromise patient safety.
The market is segmented by cytokine type into TNF (tumor necrosis factors, including TNF-alpha, used in immune activation), IL (interleukins, including IL-2 for T-cell expansion, IL-4 and IL-13 for Th2 differentiation, IL-6 for B-cell differentiation, IL-7 for T-cell development, IL-12 for Th1 differentiation, IL-15 for NK cell expansion, IL-21 for T follicular helper differentiation), IFN (interferons, including IFN-gamma for macrophage activation and Th1 responses), EGF (epidermal growth factor, used in stem cell culture and regenerative medicine), and others (GM-CSF for dendritic cell maturation, TGF-beta for regulatory T-cell differentiation, etc.). Interleukins currently represent the largest segment (approximately 40-45 percent of revenue), driven by their widespread use in T-cell expansion for CAR-T therapy. EGF and growth factors are the fastest-growing segment (approximately 14-15 percent CAGR), driven by stem cell and regenerative medicine applications.
By application, the market serves cancer and malignancy (CAR-T therapy, TCR-T therapy, NK cell therapy, tumor-infiltrating lymphocyte therapy), asthma or airway inflammation (research and therapeutic applications), arthritis (research and therapeutic applications), and others (autoimmune diseases, infectious diseases, regenerative medicine). Cancer and malignancy currently represent the largest application segment (approximately 60-65 percent of revenue), driven by the commercial success of CAR-T therapies (Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti) and the expanding pipeline of cell-based cancer immunotherapies.
2. Key Market Drivers: Cell Therapy Expansion, GMP Regulatory Requirements, and Bioprocessing Growth
The GMP grade cytokines market is driven by three primary forces: the rapid expansion of cell-based therapies globally, stringent regulatory requirements for GMP compliance in advanced therapy manufacturing, and the growth of the bioprocessing and biomanufacturing industry.
A. Cell Therapy Expansion
The global cell therapy market is growing rapidly, driven by approved products and an extensive clinical pipeline. According to Alliance for Regenerative Medicine (ARM) 2025 data, there were over 1,000 cell therapy clinical trials ongoing globally, with 25+ approved cell therapy products on the market. Each cell therapy manufacturing process requires GMP grade cytokines: CAR-T cell production requires IL-2 (for T-cell expansion), IL-7 and IL-15 (for memory T-cell formation), IL-21 (for stem cell memory T-cells), and often other cytokines for T-cell activation and differentiation. Dendritic cell vaccines require GM-CSF and IL-4 for dendritic cell generation and maturation. Stem cell therapies require various growth factors (EGF, FGF, VEGF) for stem cell maintenance, expansion, and differentiation. A user case from a CAR-T manufacturer (documented in Q1 2025) reported that using GMP grade IL-2, IL-7, and IL-15 from a single validated supplier reduced cytokine-related batch failures from 8 percent to 1 percent and simplified regulatory documentation (one drug master file covering all three cytokines).
B. GMP Regulatory Requirements
Regulatory agencies (US FDA, European Medicines Agency, China NMPA, Japan PMDA, and others) require that all components used in the manufacture of cell therapy products be manufactured under appropriate GMP standards. This includes cytokines, growth factors, culture media, enzymes, and other raw materials. The FDA Guidance on “Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)” specifies that raw materials used in cell therapy manufacturing should be qualified, including information on source, manufacturing process, purity, potency, and stability. GMP grade cytokines provide this documentation, while research-grade cytokines do not. A user case from a cell therapy startup (documented in Q4 2024) reported that using research-grade cytokines in early development required extensive qualification testing (lot-to-lot variability assessment, endotoxin testing, sterility testing) that cost US$500,000 and delayed IND filing by 8 months; switching to GMP grade cytokines eliminated this burden.
C. Bioprocessing and Biomanufacturing Growth
The bioprocessing industry—the manufacturing of biologics, cell therapies, gene therapies, and vaccines—is growing at 8-10 percent annually, driven by demand for complex therapeutics. GMP grade cytokines are essential for many bioprocessing workflows: expansion of immune cells for cell therapy manufacturing, differentiation of pluripotent stem cells (embryonic stem cells, induced pluripotent stem cells) for regenerative medicine, activation of lymphocytes for vaccine production, and quality control testing (cytokine release assays, potency assays). As bioprocessing scales from research to commercial manufacturing (from small batches of 1-10 L to 1,000-10,000 L), the demand for GMP grade cytokines scales proportionally.
Exclusive Analyst Observation (Q2 2025 Data): The GMP grade cytokines market is characterized by a significant “captive vs. merchant” supply dynamic. Large pharmaceutical companies (AbbVie, Johnson & Johnson, GlaxoSmithKline, Novartis, Roche, Pfizer, Sanofi, Bayer) often produce their own GMP grade cytokines for internal cell therapy programs, leveraging their in-house bioprocessing capabilities. However, many of these companies also purchase GMP grade cytokines from merchant suppliers (Thermo Fisher Scientific, Sino Biological, ACROBiosystems) for pipeline programs, for cytokines not available in-house, or for flexibility. Smaller biotech companies and cell therapy startups rely almost exclusively on merchant suppliers, as they lack the capital and expertise for in-house GMP cytokine production. The merchant supplier segment is growing faster (approximately 14-15 percent CAGR) than captive production (approximately 10-11 percent CAGR), as the number of cell therapy developers expands and as outsourcing becomes more common. Key merchant suppliers include Thermo Fisher Scientific (US, GIBCO brand GMP cytokines), Sino Biological (China), and ACROBiosystems (China). These companies differentiate through product quality (low endotoxin, high purity, high bioactivity), product range (wide portfolio of cytokines across multiple species and applications), regulatory documentation (drug master files, certificates of analysis, stability data), and supply reliability.
3. Competitive Landscape: Large Pharma Captive Production and Merchant Suppliers
Based on QYResearch 2024-2025 market data and confirmed by company annual reports, the GMP grade cytokines market features large pharmaceutical companies (captive producers for internal use) and merchant suppliers (selling to external customers).
Large Pharmaceutical Companies (Captive Production): AbbVie (US), Johnson & Johnson (US), GlaxoSmithKline (UK), Novartis (Switzerland), Roche (Switzerland), Pfizer (US), Sanofi (France), and Bayer HealthCare Pharmaceuticals (Germany). These companies produce GMP grade cytokines primarily for their own cell therapy, immunotherapy, and bioprocessing programs.
Merchant Suppliers (Selling to External Customers): Thermo Fisher Scientific (US, GIBCO brand), Biocon (India), Sino Biological (China), and ACROBiosystems (China).
4. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global GMP grade cytokines market will reach US$3,257 million by 2031 at a CAGR of 12.6 percent.
For cell therapy manufacturers: Source GMP grade cytokines from suppliers with drug master files on file with regulatory agencies (FDA, EMA, NMPA) to simplify IND/BLA submissions. Qualify a primary and backup supplier to mitigate supply chain risk.
For merchant supplier marketing managers: Position GMP grade cytokines not as “reagents” but as critical raw materials for cell therapy manufacturing, with documentation supporting regulatory submissions. Emphasize low endotoxin (<0.1 EU/μg), high purity (>95 percent by SDS-PAGE), high bioactivity (validated in relevant cell-based assays), and batch-to-batch consistency.
For investors: Companies with broad GMP cytokine portfolios (covering multiple interleukins, interferons, growth factors), regulatory documentation (DMFs), and established customer relationships in the cell therapy industry are positioned for above-market growth.
Key risks to monitor include competition from alternative technologies (cytokine mimetics, cytokine-antibody fusions, synthetic cytokine receptors) that may replace native cytokines in some applications, and the potential for cell therapy manufacturing to shift from ex vivo (cells expanded outside the body) to in vivo (cells expanded inside the body) approaches, reducing demand for ex vivo cytokines.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
